Oaktree Specialty Lending Corporation (OCSL) Earnings Call Transcript
November 17, 2026
Earnings Call Speaker Segments
Thank you, operator. This morning we released our earnings for the fourth fiscal quarter and the full year 2026, and you can find that release along with the slide presentation that goes with it in the investor section of our website, www.oaktreespecialtylending.com. Before we get started, I'd like to remind everyone that what we say on today's call contains forward-looking statements, which reflect current views regarding future operating results and financial performance, among other things. Actual results may differ materially from what those forward-looking statements imply or express. For a more detailed discussion of these factors, please refer to the relevant SEC filings. Oaktree has no duty to update or revise any forward-looking statements. I also want to remind you that nothing on this call is an offer to sell or a solicitation of an offer to purchase any interest in an Oaktree fund. Investors and others should note that OCSL uses the investor section of its corporate website to announce material information. The company encourages investors, the media, and others to review the information it shares on its website. On today's call, Matt Pendo, President of OCSL, will start with a progress report on fiscal 2026 priorities and an overview of our results for the fourth fiscal quarter. Armen Panossian, CEO and Co-Chief Investment Officer, will then give a market update. Raghav Khanna, Co-Chief Investment Officer, will cover portfolio activity. Chris McKown, CFO and Treasurer, will wrap up with a review of our financial results before we open the call for questions; now I'll turn the call over to Matt Pendo, President of OCSL. Matt.
Thank you, Alison, and good morning to all of you. I want to start by looking back at how we've done against the two priorities that guided us over the past year. First, bringing down non-accruals, and second, preserving flexibility on our balance sheet. After that I'll go through our financial highlights and the dividend. Beginning with non-accruals. When our fiscal year closed, non-accruals represented roughly 1.8% of the total debt portfolio at fair value; that was about 120 basis points lower than a year earlier and fairly flat versus June. Measured in dollars, non-accruals at fair value dropped from $81 million a year ago to $45 million now, which works out to a 44% reduction. Importantly, close to 85% of the drop in non-accrual dollars across the past year stemmed from proceeds we received and investments that returned to accrual status. We see this as evidence of our team's capacity to work successfully through difficult credits. Raghav will go through further updates on non-accrual positions when he speaks. Our balance sheet saw a number of favorable developments this quarter, among them a change to our ratings outlook and a bond offering. First, Moody's moved our outlook to stable in August while leaving our Baa3 rating as it was. Second, in September we priced $300 million of five-year unsecured notes due 2031 carrying a 7% coupon and a spread of 240 basis points over U.S. Treasuries. Once swapped to floating rate, the equivalent spread to SOFR comes to 258 basis points. This marked our first bond issuance in more than a year, and we were happy with how it turned out given a choppy market backdrop. Demand proved strong, with the final order book exceeding the deal size by more than three times and drawing in new OCSL bond investors. We're grateful to the fixed income community for their backing on this transaction. The added cost from the new financing comes to under half a cent per share each quarter, or $0.005 per share per quarter. Once the January 2027 notes are repaid at maturity with borrowings under our revolving credit facility, we'll have a nicely staggered maturity profile, and our next debt maturity falls in February 2029. We kept leverage conservative during the quarter, finishing September 30th at 1.00 net debt to equity. Throughout fiscal year 2026, net leverage stayed between 0.97 times and 1.07 times, comfortably within the long-term target range of 0.9 times to 1.25 times. Liquidity stood at roughly $1.04 billion at quarter end. That number is temporarily elevated since the January notes haven't been repaid yet. Pro forma for that repayment, liquidity comes to approximately $689 million, consistent with last quarter and a year ago. Now to financial highlights for our fourth fiscal quarter and fiscal year. Adjusted net investment income was $29.6 million, or about $0.34 per share, down from $32.2 million, or $0.37 per share, in the prior quarter. That decline mainly reflected a lower average portfolio balance and a higher income base incentive fee. When you look at the entire fiscal year, adjusted net investment income came in at $131.7 million, equal to $1.49 per share, versus $151.3 million, or $1.76 per share, in the 2025 fiscal year. Let me move on to the dividend. A total cash dividend of $0.32 per share for the quarter was declared by our board, made up of a base cash dividend of $0.30 per share plus a supplemental dividend of $0.02 per share. Cash payment of these dividends is scheduled for December 31, 2026. The record date for stockholders is December 15, 2026. As a reminder, back in May we adjusted the base dividend so that it would be covered by earnings at our current conservative leverage, and we kept the supplemental dividend at 50% of adjusted net investment income above the base dividend. Across fiscal 2026, declared dividends came to $1.39 per share, amounting to 108% of adjusted net investment income. Looking ahead to fiscal 2027, our top priorities remain the same: resolve non-accruals, exit equity positions that are not producing income, and redeploy those proceeds into performing assets. Given net leverage of 1.00 times and pro forma liquidity of nearly $700 million, we have the flexibility to act opportunistically when new investments and strategic opportunities come up; with that, I'll hand the call over to Armen to talk about the market environment.
Thank you, Matt. Because this call marks the end of our fiscal year, I'd like to set where things stood twelve months ago alongside where they stand now. Back then, the Fed had only just lowered rates in September and October, and the market was expecting further cuts in 2026 as well as a pickup in M&A activity. Both of those forecasts failed to pan out. What markets got instead was greater volatility in early 2026, driven by worries about AI disruption, geopolitical uncertainty, and inflation pressures that returned. That serves as a useful reminder of why Oaktree's approach to investing rests on fundamental credit analysis instead of macro forecasting. Now let's jump to the present. With Brent crude climbing past $100 per barrel in the September quarter and heavy AI-related CapEx feeding inflation pressures, the Fed did the opposite and lifted rates by 25 basis points, bringing the federal funds rate to 3.75%-4%, while the 10-year Treasury yield broke through the symbolic 5% mark, its highest in almost two decades. Twelve months ago the question was how far rates would drop. Now the question is how long they remain elevated and how high they go. In our view, short-term base rates moving from roughly 4% to 5% would still be manageable and might even help investor returns, since most of that increase would pass through into net investment income. On the OCSL side, floating-rate exposure accounts for 91% of what we hold in debt investments. As loans reset, a higher base rate therefore increases the contractual interest income we receive. The next thing we weigh is borrower capacity to absorb higher rates. For each borrower, we run interest coverage through multiple base rate scenarios, and during underwriting we add cushion to the capital structure. If we look at borrower results over the trailing 12 months, weighted average interest coverage comes in at 2.3 times. A 100 basis point increase in base rates would leave coverage at approximately 2.1 times, which is still above the trough of about 1.9 times that our portfolio experienced in late 2023 and early 2024. Set against this shift in the rate environment, credit market results during the quarter were mixed. U.S. leveraged loans gained close to 2%, helped by floating rate coupons that reduce sensitivity to rising rates, whereas high-yield bonds fell by almost 2% as Treasury yields climbed. Corporate fundamentals stayed broadly resilient, yet the weakest leverage credits underperformed, a sign of increasingly selective investor appetite and the mounting strain of elevated borrowing costs. Turning to deal activity, direct lending volume picked up slightly in September, even though year-to-date deal flow and average deal size stayed under last year's levels. For most deals, capital is still competitive—even though a lot of the biggest non-traded BDCs have pulled back—so supply and demand sit in reasonable balance. Pricing on new first lien loans backed by sponsors held steady for months at SOFR plus 500 to 550 basis points, which is about 50 to 100 basis points wider than where things stood at the close of 2025. With the broadly syndicated loan market continuing to tighten over the quarter, the extra yield that fresh direct lending originations offered relative to new broadly syndicated loans climbed past 150 basis points. Bringing everything together, our attention stays on the things we can control, and we believe we are well positioned even if rates stay higher for longer and the environment grows more volatile; with that, I'll hand the call to Raghav, who will review our investment activity and portfolio.
Thanks, Armen. I'll begin with new originations and exits, then cover non-accruals, and finish with portfolio metrics. On originations, new investment commitments came to $179 million for the quarter, versus $206 million in the prior quarter and $208 million in the fourth fiscal quarter of 2025. Our pipeline has built steadily since late September, and we originated roughly $80 million of new investment commitments in October. During the quarter, new debt investments carried a weighted average yield of 9.6%, while spreads on new originations came in at roughly 570 basis points—above the 500-to-550 market spread range. Among the quarter's notable transactions was a first lien loan to Outcomes First Group, listed on our schedule of investments as OFS Bidco. Outcomes First Group holds the position of the U.K.'s largest independent provider of schools for children and youth with special educational needs and disabilities. The facility totaled GBP 600 million in first lien debt, approximately 75% of which was funded upfront, priced at SONIA + 525 basis points with 1.5 points of OID. This deal allowed the company to refinance what it already owed and also helps it grow more, including abroad. Because Oaktree has had a relationship with the sponsor, PPG, for a long time, we became the anchor lender. Our European private debt team, which knows the local markets well and works directly with management, underwrote and structured this investment. What draws us to the company is its lengthy operating history, a footprint that would be hard to replicate, the high quality of its schools, and strong visibility into revenue; it also competes in an industry enjoying multiple demand tailwinds, among them statutory funding obligations, a structural supply shortage that persists, and high barriers to entry. This transaction shows how much value comes from pairing local presence and regional expertise with relationships around the world. In the quarter, we completed three equity investments that generate income, lifting equity exposure to 5.5% of fair value, up from 3.9% in the prior quarter. These deals are heavily structured with downside protection we negotiate, and they provide attractive risk-adjusted returns for the portfolio. Turning to exits and prepayments: proceeds from prepayments, exits, other paydowns, and sales totaled $198 million, compared with $263 million last quarter and $177 million a year ago. Several private investments were fully repaid during the quarter. Certain borrowers were taken out through the broadly syndicated loan market, while others were refinanced with different private lenders. One exit worth highlighting this quarter was RumbleOn repaying its first lien term loan—shown on our schedule of investments as RideNow Group, a public company running power sports retail dealerships plus an e-commerce operation. We served as agent on that term loan, first funded in 2021 to support RumbleOn's purchase of the RideNow power sports platform. Integration struggles and weaker consumer spending following COVID hurt EBITDA and raised the risk of a covenant breach, which led us to mark the loan down to 94 during 2023. What matters is that the very structured nature of our loan stopped value from leaking out while the company underperformed, and we collaborated closely with the company on a turnaround plan that brought in new management, cut costs, sold assets, and raised capital. Those steps put the company back on a growth footing, and we were ready to give the company relief through covenant resets and a maturity extension in return for debt paydowns made during that period so the balance sheet could be rightsized; in September, RumbleOn refinanced its term loan, and the $35 million position we still held was repaid at 101, exit fee included, one year before the 2027 maturity. That stands as one more illustration of how our focused structuring capabilities, patience, teamwork with management teams, and discipline produced a positive result for OCSL stakeholders. Now to non-accruals. As of September 30th, six companies sat on non-accrual, unchanged from last quarter and lower than 10 a year ago. At fair value, non-accruals made up roughly 1.8% of the total debt portfolio.
That works out to 4% of the total debt portfolio at cost as well, and on a cost basis it's 20 basis points lower than last quarter and 250 basis points lower than a year ago. One investment came off non-accrual, a new tranche was added within an existing non-accrual name, and one new borrower joined the list. BayMark left non-accrual after lenders decided to recapitalize and stabilize the business; we placed the first out term loan of Pluralsight on non-accrual as that company continues to underperform expectations. As a reminder, back in December 2025 we put the second out term loan on non-accrual and wrote our equity down to zero. The new name placed on non-accrual this quarter is BioXcel Therapeutics, a publicly traded biopharmaceutical company, though we expect a fairly quick resolution in the December quarter. BioXcel filed for Chapter 11 in late August 2026 with an up to $125 million stalking horse proposal from Teva, a large global pharmaceutical company. The court-supervised process moved fast, and in late October a sale to Teva closed at a value consistent with our carrying mark of 83. Teva funded $57.5 million upfront at closing, with the remainder payable upon certain regulatory and commercial thresholds; we're pleased to report that on November 13th Teva received FDA approval for BioXcel's drug, which has triggered the full $67.5 million additional milestone to the lenders. That is expected to be paid within 30 days and will produce a realized value well above our carrying mark. Wrapping up the non-accrual discussion is an update on Praxio. As a reminder, last quarter 80% of the debt was paid down, and the small remaining amount went back to accrual status. In early November, the balance was paid in full at par. Turning to total portfolio metrics as of September 30th, 79.1% of the portfolio at fair value was first lien senior secured debt. The weighted average yield on debt investments was 9.4%, versus 9.3% last quarter. The portfolio stays well-diversified, with 170 portfolio companies. The average debt position is roughly 62 basis points of the total portfolio at fair value, and no single position is above 2.1%. Median EBITDA for portfolio companies was about $180 million. Portfolio company weighted average leverage was 5.1 times, and interest coverage was 2.3 times. Both metrics held steady sequentially and against a year ago. On software, under GICS industry group classification, software accounts for 20% of the portfolio at fair value, unchanged sequentially and down from 24% a year ago. 94% of our software positions are first lien, and ARR-based loans make up just 0.8% of the portfolio. Our high AI risk software exposure is relatively unchanged at approximately 3% of the performing debt portfolio; with that, I'll hand the call to Chris to review our financial results.
Thanks, Raghav. Adjusted total investment income for our fourth fiscal quarter, which closed on September 30, 2026, came in at $68.0 million, lower than the $69.2 million we recorded in the prior quarter. That sequential decline was mostly due to a lower average portfolio balance. For the fiscal year, adjusted total investment income came in at $281.4 million, compared with $315.4 million a year earlier. The year-over-year decrease was mainly caused by lower reference rates, together with a smaller average portfolio balance. The year-over-year decrease was mainly caused by lower reference rates, together with a smaller average portfolio balance. Adjusted net investment income was $29.6 million, or $0.34 per share, compared with $32.2 million, or $0.37 per share, in the prior quarter. That sequential decrease reflected lower total investment income and a larger income-based, or Part I, incentive fee, partly offset by lower interest and other expenses. For the full year, adjusted net investment income totaled $131.7 million, or $1.49 per share, versus $151 million, or $1.76 per share, in fiscal 2025, with drivers similar to those behind the quarterly results. On the incentive fee, we paid $4.8 million this quarter, roughly $0.05 per share, versus $2.4 million last quarter, or $0.03 per share. A full quarterly incentive fee would have been roughly $6.0 million, so our total return hurdle reduced the fee by about $1.2 million, or around $0.01 per share, in the September quarter. For the full year, the incentive fee paid was $8.4 million, or $0.10 per share. Over the past year, our total return hurdle reduced incentive fees by $16.1 million. We believe this mechanism is working as intended, linking the fees Oaktree earns to the total returns shareholders receive. Beginning with the December quarter, the September rate hike will start flowing through into net investment income. Because 91% of our debt investments carry floating rates and 100% of our debt is floating or swapped to floating, the net effect is positive, assuming nothing else changes. Resets are somewhat staggered across the portfolio, but most of the impact will appear in our December quarter earnings, with the full effect building from there. Once resets are complete, each 25 basis point increase in base rates adds a bit more than half a penny per share per quarter to adjusted net investment income, or a little over $0.02 per share on an annualized basis. Now to NAV. NAV per share was $15.63 as of September 30, a 0.4% decrease from $15.70 in June. PIK income represented roughly 7.3% of adjusted total investment income in the quarter, down from 7.8% last quarter. About 75% of total PIK income is tied to investments that were structured at origination with the option to PIK. Investments that generated non-cash income during the quarter carry a weighted average fair value of approximately 98. Net leverage at quarter end was 1.00x, versus 1.02x last quarter and 0.97x a year ago. Our long-term target leverage range of 0.9x to 1.25x is unchanged. Total debt outstanding at quarter end was $1.42 billion. Our liquidity was approximately $1.4 billion, and Teva funded $575 million upfront at closing, compared with $95 million a year ago. As of September 30, the debt still on the books had a weighted average interest rate of 6.2%, compared with 5.9% in the previous quarter and 6.5% a year before. After accounting for the new 2031 notes, the repayment of the 2027 notes, and the higher base rate, the pro forma interest rate on debt works out to 6.4%. At the close of the quarter, unsecured debt represented approximately 88% of total debt, versus 65% last quarter and 64% a year ago. Had the expected repayment of the 2027 notes been reflected, unsecured debt would have been about 64% of total debt at quarter end. Our liquidity was approximately $1.4 billion, comprising $45 million of cash and $994 million of undrawn capacity under our credit facilities. If the 2027 notes were repaid at maturity, liquidity would have come to roughly $689 million, compared with $699 million in the prior quarter and $695 million a year ago. Unfunded commitments, excluding those related to the JVs, came to about $226 million. I'll wrap up with our JVs. Together, the JVs held roughly $547 million of investments across 144 portfolio companies and generated aggregate returns on equity of about 11.5% for the quarter. Leverage at the JVs was 2.0 times, versus 2.1 times last quarter. With that, I'll turn the call back to the operator for Q&A.
It seems PIK has drifted downward somewhat since the June quarter. Did the restructuring cause that, or could you fellows just take me through how the portfolio has changed?
Hi, Sean- Paul, this is Chris. Appreciate the question. Sure, regarding that quarter-on-quarter downtick, as we noted earlier in the prepared remarks, BioXcel was moved to non-accruals. That contributed to the impact. We anticipate a quick resolution on that front. Then there was another factor: we had a royalty interest that had previously been PIKing, and we exited it during the quarter. Those were the two main drivers.
Understood. Thanks for taking the call.
Hi, guys. I've just got a quick one. Could you review your capital allocation priorities? You mentioned there's some room to bring leverage higher should you choose to. You mentioned staying flexible on the balance sheet, but please walk through how you balance deployment, repurchases, leverage, and so on. Thanks so much.
Hi, Ethan. This is Matt. Thanks for asking; every quarter we speak with the board about capital allocation. We want to approach it thoughtfully. Since we took over management, we haven't repurchased shares, for a couple of reasons. I think the main one is simply the desire to have capital available to keep investing in portfolios and attractive loans that we see. That remains priority number one, really. Across 2026, we ran leverage at 0.97 to 1.07. As I said on the call, our target is 0.9 to 1.25. We finished the year at one time, so we definitely, and as Chris walked through our liquidity and capital, we have plenty of capital; so I think our main focus is deploying into attractive investment opportunities. We have the capital; we're comfortable taking leverage up within the range we've run over the last year, 0.97, 1.07. So I think that's where our focus will be.
Great. And I suppose one more quick question. I think previously, you've sort of described the credits that have underperformed as perhaps businesses that had trouble with post-COVID normalization. Credit performance appears to have stabilized nicely over the last couple of quarters; but I'm curious whether you feel the impact from that trend has largely subsided, maybe except for Pluralsight.
Yeah. Hey, Sean. Hey, Ethan. I can take that one. You're right. Most of the big declines in 2021 and 2022 came from post-COVID normalizations, but also, honestly, many of the capital structures put in place in 2021 and early 2022 simply were not set up for base rates in the low fours to five. Those were the main reasons. I think going forward, and what you're seeing right now, is the non-accruals. The one non-accrual that was added, the new name, is largely due to idiosyncratic reasons. To give you some color, the name that was added is the largest opioid treatment center business in the U.S. When you think about the end market, it isn't cyclical, and frankly, the revenues have not been cycling. They had an idiosyncratic issue in revenue collection because of bad ERP systems, which is what led to the restructuring. When we see problems in the portfolio now, they are idiosyncratic rather than because of one big theme.
Great. Yeah, that was the crux of my question. Thanks very much.
Ethan, just to follow up, I do think, and we talked about it on the call, like the progress in BioXcel, I still think there is progress we can make on the existing non-accruals.
Thanks to everyone for being with us on today’s call. If you have any questions, please don’t hesitate to contact me and the team. Have a great day, all.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Oaktree Specialty Lending Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Oaktree Specialty Lending Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.